A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

NCT05552326 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

446

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Hypertriglyceridemia

Interventions

DRUG: Olezarsen
DRUG: Placebo

Sponsor

Ionis Pharmaceuticals, Inc.